National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

haloperidol
A phenylbutylpiperadine derivative with antipsychotic, neuroleptic, and antiemetic activities. Haloperidol competitively blocks postsynaptic dopamine (D2) receptors in the mesolimbic system of the brain, thereby eliminating dopamine neurotransmission and leading to antidelusionary and antihallucinagenic effects. Antagonistic activity mediated through D2 dopamine receptors in the chemoreceptive trigger zone (CTZ) accounts for its antiemetic activity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand name:Haldol
Code names:McN-JR-1625
R-1625
Chemical structure name:4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone



Previous:Haelan 951, Haemophilus influenzae b vaccine, Haldol, Halodrin, halofuginone hydrobromide
Next:Halotestin, Havrix, HDAC inhibitor CHR-3996, HDAC inhibitor CRA-024781, HDAC inhibitor ITF2357

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov